DE3405581A1 - Pharmazeutische zusammensetzung mit metabolischer und energetischer wirksamkeit zur verwendung in der herz- und gefaesstherapie - Google Patents

Pharmazeutische zusammensetzung mit metabolischer und energetischer wirksamkeit zur verwendung in der herz- und gefaesstherapie

Info

Publication number
DE3405581A1
DE3405581A1 DE19843405581 DE3405581A DE3405581A1 DE 3405581 A1 DE3405581 A1 DE 3405581A1 DE 19843405581 DE19843405581 DE 19843405581 DE 3405581 A DE3405581 A DE 3405581A DE 3405581 A1 DE3405581 A1 DE 3405581A1
Authority
DE
Germany
Prior art keywords
coenzyme
carnitine
pharmaceutical composition
metabolic
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19843405581
Other languages
German (de)
English (en)
Other versions
DE3405581C2 (https=
Inventor
Alberto Mailand/Milano Bertelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of DE3405581A1 publication Critical patent/DE3405581A1/de
Application granted granted Critical
Publication of DE3405581C2 publication Critical patent/DE3405581C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE19843405581 1983-02-16 1984-02-16 Pharmazeutische zusammensetzung mit metabolischer und energetischer wirksamkeit zur verwendung in der herz- und gefaesstherapie Granted DE3405581A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH858/83A CH655005A5 (it) 1983-02-16 1983-02-16 Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.

Publications (2)

Publication Number Publication Date
DE3405581A1 true DE3405581A1 (de) 1984-10-18
DE3405581C2 DE3405581C2 (https=) 1992-10-22

Family

ID=4196830

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19843405581 Granted DE3405581A1 (de) 1983-02-16 1984-02-16 Pharmazeutische zusammensetzung mit metabolischer und energetischer wirksamkeit zur verwendung in der herz- und gefaesstherapie

Country Status (11)

Country Link
US (1) US4599232A (https=)
JP (1) JPS59186914A (https=)
BE (1) BE898918A (https=)
CH (1) CH655005A5 (https=)
DE (1) DE3405581A1 (https=)
DK (1) DK165167C (https=)
FR (1) FR2543827B1 (https=)
GB (1) GB2137088B (https=)
IT (1) IT1170235B (https=)
NL (1) NL192778C (https=)
SE (1) SE457143B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001740A1 (en) * 1987-08-27 1989-03-09 Sockerbolaget Ab Diet fortification
DE4335454A1 (de) * 1993-10-19 1995-04-20 Schleicher Peter Geriatrikum
EP1251834A4 (en) * 2000-01-20 2008-11-05 Raj K Chopra REDUCED FORM OF COENZYME Q IN STABLE DOSAGE FORMS WITH HIGH BIOAVAILABILITY AND CORRESPONDING APPLICATIONS

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1209519B (it) * 1984-04-10 1989-08-30 Poli Ind Chimica Spa Composti ad attivita'cardiotrofica.
CH662505A5 (it) * 1985-04-30 1987-10-15 Seuref Ag Composizioni farmaceutiche ad azione protettiva vascolare.
CH670763A5 (https=) * 1985-08-02 1989-07-14 Seuref Ag
CH666183A5 (it) * 1985-08-06 1988-07-15 Seuref Ag Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare.
IT1184655B (it) * 1985-10-14 1987-10-28 Sigma Tau Ind Farmaceuti Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
GB8907276D0 (en) * 1989-03-31 1989-05-17 Therapy Advisory Services Limi Health supplement
AT393954B (de) * 1990-02-28 1992-01-10 Bock Orthopaed Ind Verfahren und vorrichtung zur bestimmung von gebrauchseigenschaften eines prothesenschaftes
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
ATE271614T1 (de) * 1992-05-28 2004-08-15 Ct For Molecular Biology And M Quinone-derivate zur verbesserung der zellulare bioenergie
US5707971A (en) * 1995-06-07 1998-01-13 Life Resuscitation Technologies, Inc. Modulation of glycolytic ATP production
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
DK0969744T3 (da) * 1997-03-27 2003-06-23 Khursheed N Jeejeebhoy Kosttilskud til forbedringer af celleenergetik
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US5973004A (en) * 1997-04-04 1999-10-26 Howard; James R. L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquinone, combined for prevention and treatment of syndromes related to ineffective energy metabolism
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
US5916912A (en) * 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US20050196470A9 (en) * 1998-04-03 2005-09-08 Wuh Hank C Method and composition for enhancing sexual desire
IT1299266B1 (it) * 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
WO2001021208A1 (en) 1999-09-23 2001-03-29 Juvenon Corporation Nutritional supplement for increased energy and stamina
US20070072927A1 (en) * 1999-09-23 2007-03-29 Vita Joseph A Nutritional supplement for increased energy and stamina
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
CA2389623A1 (en) 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
JP2003529347A (ja) * 2000-01-25 2003-10-07 ジュヴェノン インコーポレイテッド 高齢ペット用の栄養補給食品
DE10036798A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Mittel zur Behandlung der Haare und der Kopfhaut
US6441050B1 (en) 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US6497885B2 (en) 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US6579866B2 (en) 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning
US20060062864A1 (en) * 2000-12-28 2006-03-23 Mccleary Edward L Weight loss composition and method
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
EP1388340B1 (en) * 2001-05-10 2010-09-08 Kaneka Corporation Compositions for transmucosal administration containing coenzyme q as the active ingredient
WO2003002147A1 (en) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Preventives/remedies for organ functional disorders and organ dysfunction
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
WO2005006890A2 (en) * 2003-07-10 2005-01-27 Forest Carl A Foods, beverages, condiments, spices and salad dressings with specialized supplements
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US8105583B2 (en) * 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
WO2006012267A1 (en) * 2004-06-29 2006-02-02 Elixirin Corporation Dietary compositions for enhancing metabolism and reducing reactive oxygen species
EP2471530B1 (en) 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US20050249803A1 (en) * 2005-06-03 2005-11-10 Udell Ronald G Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
CA2622523C (en) * 2005-09-15 2014-02-18 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20100022629A1 (en) * 2006-01-13 2010-01-28 Elixirin Dietary Methods and Compositions for Enhancing Metabolism and Reducing Reactive Oxygen Species
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20080020022A1 (en) * 2006-06-05 2008-01-24 Udell Ronald G Chewable co-enzyme q-10 capsule
EP1970761B1 (en) * 2007-03-14 2012-02-29 FUJIFILM Corporation Photosensitive composition and method of producing a cured relief pattern
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
ES2306610B1 (es) * 2007-04-16 2009-09-11 Universidad De Sevilla Uso de la l-carnitina para el tratamiento de la hipertension arterial.
TW200918096A (en) * 2007-06-22 2009-05-01 Kaneka Corp Composition comprising bioactive substance
TW200916090A (en) * 2007-06-22 2009-04-16 Kaneka Corp Composition comprising coenzyme Q10
EP2186789B1 (en) * 2007-08-22 2013-12-25 Kaneka Corporation Method of producing reduced coenzyme q10 and method of stabilizing the same
KR101325374B1 (ko) * 2008-02-19 2013-11-08 가부시키가이샤 오츠까 세이야꾸 고죠 신체 기능의 회복에 유용한 경구 또는 경장 조성물
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255449A (en) * 1978-02-03 1981-03-10 Claudio Cavazza Method of treating abnormal lipoprote in ratios
US4343816A (en) * 1979-02-12 1982-08-10 Claudio Cavazza Pharmaceutical composition comprising an acyl-carnitine, for treating peripheral vascular diseases
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255449A (en) * 1978-02-03 1981-03-10 Claudio Cavazza Method of treating abnormal lipoprote in ratios
US4343816A (en) * 1979-02-12 1982-08-10 Claudio Cavazza Pharmaceutical composition comprising an acyl-carnitine, for treating peripheral vascular diseases
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
b) S. 197-201, 1982 *
c) S. 187-191, 1982 *
C.A. 1980, 93, 197857i *
C.A. 1981, 95, 12776g *
d) S. 183-186, 1982 *
Int. J.Tissue React 90 Vol. 12(3) a) S. 193-196, 1982 *
Oncology 88, Vol. 45, 242-6 1982 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001740A1 (en) * 1987-08-27 1989-03-09 Sockerbolaget Ab Diet fortification
DE4335454A1 (de) * 1993-10-19 1995-04-20 Schleicher Peter Geriatrikum
EP1251834A4 (en) * 2000-01-20 2008-11-05 Raj K Chopra REDUCED FORM OF COENZYME Q IN STABLE DOSAGE FORMS WITH HIGH BIOAVAILABILITY AND CORRESPONDING APPLICATIONS

Also Published As

Publication number Publication date
DK165167C (da) 1993-03-01
DK72284D0 (da) 1984-02-16
GB2137088A (en) 1984-10-03
FR2543827B1 (fr) 1987-06-12
DK165167B (da) 1992-10-19
IT8323559A0 (it) 1983-10-31
NL192778B (nl) 1997-10-01
US4599232A (en) 1986-07-08
JPH027572B2 (https=) 1990-02-19
IT1170235B (it) 1987-06-03
SE457143B (sv) 1988-12-05
SE8400851D0 (sv) 1984-02-16
CH655005A5 (it) 1986-03-27
FR2543827A1 (fr) 1984-10-12
BE898918A (nl) 1984-08-16
DK72284A (da) 1984-08-17
NL8400488A (nl) 1984-09-17
GB2137088B (en) 1986-02-05
DE3405581C2 (https=) 1992-10-22
JPS59186914A (ja) 1984-10-23
SE8400851L (sv) 1984-08-17
NL192778C (nl) 1998-02-03
GB8403668D0 (en) 1984-03-14

Similar Documents

Publication Publication Date Title
DE3405581C2 (https=)
DE69909775T2 (de) Neue fettanaloge zur behandlung von diabetes
DE2817358C2 (https=)
DE69022678T2 (de) S(+)-Ibuprofen-L-Aminosäure und S(+)-Ibuprofen-D-Aminosäure als Analgetika mit grösserem pharmakologischem Potential.
DE69938179T2 (de) Kombination von riluzol und levodopa zur behandlung von morbus parkinson
DE2621214B2 (de) Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und dessen Mineralsalzen
DE3200016C2 (https=)
DE69826674T2 (de) Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend
DE3715218A1 (de) Arzneimittel zur stimulation des lernens und zur verbesserung des gedaechtnisses
DE60313886T2 (de) Zusammensetzung von einem PPAR-alpha Agonisten und Metformin zur Behandlung von Obesitas
DE3000139A1 (de) Die verwendung von glyzerinphosphorylderivaten in der therapie der dislipaemie, der hepatitis und vergleichgeeignete pharmazeutische kompositionen
DE3035494A1 (de) Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels
DE69407684T2 (de) Verwendung von L-Carnitine oder Acyl-L-Carnitinen und Valproat zur Behandlung von Anfallserkrankungen
DE3609005A1 (de) Pharmazeutische zusammensetzungen mit metabolischer aktivitaet
DE3625459C2 (https=)
EP0472033B1 (de) 3,5-Diiod-L-Thyronin zur TSH-Suppression und Behandlung von Struma
DE2846335A1 (de) Derivate des d,l- bzw. l-carnitins sowie diese enthaltende arzneimittel
DE69533742T2 (de) Verwendung von Prolin und/oder Derivaten als Mittel gegen Hepatitis
DE1667903C3 (de) Verwendung von Cysteinderivaten zur Herstellung von per oral verabreichbaren Mitteln zur Bekämpfung der Seborrhoe
DE3339052A1 (de) Pharmazeutisches praeparat zur verbesserung der biochemischen und verhaltens-parameter bei senilitaet
Essig Barbiturate withdrawal convulsions in decerebellate dogs
DE2128730A1 (de) Mittel zur Kompensierung eines Dopaminmangels im Gehirn
DE2953014A1 (en) Osteoplastic promotor
DE3240650A1 (de) Pharmazeutische zusammensetzung zur therapie infektionsbedingter nierensteinbildung
DE60020888T2 (de) Zusatz aus kräutern zur behandlung von kognitiven störungen aufgrund von östrogenverlust

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Free format text: HOFFMANN * EITLE, 81925 MUENCHEN